Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

Gynecologic Oncology
Martee L HensleyCarol A Aghajanian

Abstract

Patients with completely resected stages I-IV high grade uterine leiomyosarcoma are at high risk for recurrence. No adjuvant treatment has been shown to improve survival, although prospective data are limited. We sought to determine whether adjuvant gemcitabine-docetaxel would yield a 2-year progression-free survival of at least 50% in this leiomyosarcoma population. Eligible patients were treated with gemcitabine 900 mg/m(2) over 90 min days 1 and 8 plus docetaxel 75 mg/m(2) day 8, every 3 weeks for 4 cycles. CT imaging was performed at baseline, after cycle 4, and every 3 months. Progression was defined as evidence of new disease on CT. Twenty-five patients (median age 49; range, 37-73) enrolled; 23 were evaluable (1-never treated, 1-ineligible). With median follow-up of 49 months for all patients, 10 (45%) of the 23 evaluable patients remained progression free at 2 years, with a median progression-free survival of 13 months. The median overall survival is not yet reached. Among the 18 patients with stages I or II uterine leiomyosarcoma, 59% remain progression-free at 2 years, with a median progression-free survival of 39 months. Median overall survival for stages I and II patients is not yet reached with median follow-up dur...Continue Reading

References

Oct 1, 1982·The American Journal of Surgical Pathology·M E KingR E Scully
Nov 1, 1996·Gynecologic Oncology·A GadducciA Fanucchi
Aug 6, 2000·Gynecologic Oncology·D M KushnerM Markman
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martee L HensleyDavid R Spriggs
Aug 12, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K OdunsiS Lele
Sep 16, 2008·Gynecologic Oncology·Oliver ZivanovicNadeem R Abu-Rustum

❮ Previous
Next ❯

Citations

Sep 11, 2013·Gynecologic Oncology·Stephanie RicciAmanda Nickles Fader
Mar 9, 2011·Current Treatment Options in Oncology·Anna PatrikidouAxel Le Cesne
Jul 16, 2014·Clinical Sarcoma Research·Eirini ThanopoulouIan Judson
Sep 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO/European Sarcoma Network Working Group
Apr 10, 2009·World Journal of Surgical Oncology·Flora ZagouriChristos A Papadimitriou
Jun 12, 2009·Der Pathologe·G Köhler
May 21, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Elena García-MartínezAntonio González-Martín
Mar 2, 2011·Current Treatment Options in Oncology·Michelle Scurr
Jun 19, 2013·Current Treatment Options in Oncology·Alessandro Gronchi, Paolo G Casali
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Eriksson
Apr 6, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiP G Casali
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO / European Sarcoma Network Working Group
Oct 19, 2013·Current Oncology Reports·Nicholas Reed
Nov 12, 2015·Critical Reviews in Oncology/hematology·Agnès DucoulombierNicolas Penel
Oct 8, 2013·Hematology/oncology Clinics of North America·César Serrano, Suzanne George
May 31, 2013·Current Problems in Cancer·Kenneth Cardona, Sujana Movva
Mar 1, 2012·Surgical Oncology Clinics of North America·Vinod Ravi, Shreyaskumar Patel
Sep 16, 2011·Gynecologic Oncology·Roberta SanfilippoPaolo Giovanni Casali
Mar 18, 2011·Medicina clínica·Xavier García Del MuroUNKNOWN Grupo Español de Investigación en Sarcomas (GEIS)
Jan 21, 2011·European Journal of Radiology·Beatrice M Seddon, Reena Davda
Aug 29, 2009·Gynecologic Oncology·Gloria S HuangGary L Goldberg
Jun 13, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elizabeth J DavisScott M Schuetze
Oct 5, 2015·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Jaime Prat, 'Nomonde Mbatani
Apr 14, 2016·Journal of Cancer Research and Therapeutics·Mustafa Cosan TerekAhmet Aydin Ozsaran
Nov 25, 2014·Expert Opinion on Pharmacotherapy·Angiolo Gadducci, Maria Elena Guerrieri
May 15, 2013·International Journal of Surgery·David Cantú de LeónLuis Alonso Herrera
May 12, 2015·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xiaoli WuQing Xu
Dec 4, 2013·Gynecologic Oncology·Titilope OduyeboMichael G Muto
Jul 3, 2010·World Journal of Surgical Oncology·Achraf ShamseddineAli Shamseddine
Oct 28, 2016·Cancer Chemotherapy and Pharmacology·Michael J Nathenson, Edward Sausville
Sep 4, 2016·Taiwanese Journal of Obstetrics & Gynecology·Kuo-Chang WenUNKNOWN Taiwan Association of Gynecology Systematic Review Group
Oct 9, 2016·Current Oncology Reports·Michael J NathensonAnthony Conley
Jul 20, 2016·Minimally Invasive Therapy & Allied Technologies : MITAT : Official Journal of the Society for Minimally Invasive Therapy·Wenxiao JiangXueqiong Zhu
Mar 20, 2016·Journal of Clinical Pathology·Glauco BaiocchiIsabela Werneck Cunha
Jan 28, 2017·BJOG : an International Journal of Obstetrics and Gynaecology·R R CuiJ Y Hou
Oct 27, 2009·Gynecologic Oncology·Emanuela D'Angelo, Jaime Prat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinosarcoma

Carcinosarcoma is a malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. Discover the latest research on carcinosarcoma here.